期刊文献+

肾性高血压治疗进展 被引量:17

Progress of treatment of renal hypertension
下载PDF
导出
摘要 高血压既是慢性肾脏病的始动因素,也是慢性肾脏病的进展因素,还是慢性肾脏病患者心血管并发症的高危因素。因此,对于肾脏病合并高血压必须积极治疗。根据病因和发病机制不同,肾性高血压又可分为肾实质性和肾血管性高血压,但无论何种原因、何种类型高血压,控制血压达标均是治疗关键所在。本文从肾性高血压最佳目标血压水平、生活方式的调整、不同亚型临床治疗方式的选择及进展作一介绍。 Hypertension is an initiating and progressive factors for chronic kidney disease, and it is also a high risk factor for promoting cardiovascular complications of chronic kidney disease patients. So we should take active measures to treat renal disease complicated by hypertension. According to different etiopathogenisis and pathogenesis, renal hypertension could be divided into renal parenehymal hypertension and renal vascular hypertension. Blood pressure control is critical to any type of hypertensions. This article will elucidate some advances in the treatment of renal hypertension, such as optimal blood pressure level, adjustment of life style and treatment options for different subtypes.
作者 刘章锁
出处 《实用医院临床杂志》 2008年第4期22-24,共3页 Practical Journal of Clinical Medicine
关键词 高血压 肾脏病 治疗 Hypertension Renal disease Treatment
  • 相关文献

参考文献11

  • 1[1]Ruilope LM,Salvetti A,Jamerson K,et aL Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study[J].J Am Soc Nephrol,2001,12(2):218-225.
  • 2[2]Maschio G,Alberti D,LocateUi F,et aL Angiotensin-converting enzyme inhibitors and kidney protection:the AIPRI triaL The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group[J].J Cardiovasc Pharmacol,1999,33(suppl 1):S16-20.
  • 3[3]Hou FF,Zhang X,Zhang GH,et al.Efficacy and safety of benazepril for advanced chronic renal insufficiency[J].N Engl J Med,2006,354 (2):131-140.
  • 4[4]Ruggenenti P,Pema A,Gherardi G,et aL Renal function and require-ment for dialysis in chronic nephropathy patients on long-term ramipril:REIN follow-up trial.Gruppo Italiano di Studi Epidemiologici in Nefrolo-gia (GISEN)[J].Lancet,1998,352(9136):1252-1256.
  • 5[5]Parring HH,Lehnert H,Brochner MJ,et aL The effect of irbesartan on the development of diabetic ncphropathy in patients with type 2 diabetes[J].N Engl J Med,2001,345(12):870-878.
  • 6[6]Giancarlo V,Nigel MW.Microalbuminuria reduction with valsartan in patients with type-2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106(3):672-678.
  • 7[7]Lewis EJ,Nunsicker LG,Clarke WR,et aL Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephrcpathy due to type 2 diabetes[J].N Engl J Med,2001,345(12):851-860.
  • 8[8]Brenner BM,Cooper ME,Zecuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2diabetes and nephrop-athy[J].New Engl J Meal,2001,345(12):861-869.
  • 9[9]Julius S,Kjeldsen SE,Weber M,et aL Outcomes in hypertensive pa-tients at high cardiovascular risk treated with regimens based on valsrtan or andodipine:the VALUE randomized trial[J].Lancet,2004,363(9426):2022-2031.
  • 10[10]Wachtell K,Dahlof B,Rokkedal J,et aL Change of left ventrieular geo-metric pattern after 1 year of antihypertensive treatment:the Losartan In-tervention For Endpoint reduction in hypertension(LIFE) study[J].J Am Heart,2002,144(6):1057-1064.

同被引文献105

引证文献17

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部